"One-Stop" Composite Technology(hybrid) Application in Coronary Heart Disease Research

LIU Xiao-ming,LIU Ji-chun,ZHOU Xue-liang,YU Ben-tong,WU Qi-cai,WAN Li
DOI: https://doi.org/10.3969/j.issn.1002-266x.2012.33.015
2012-01-01
Abstract:Objective To evaluate the feasibility,safety,and clinical outcomes of the hybrid coronary artery bypass grafting surgery in 8 patients.Methods Hybrid coronary artery bypass grafting surgery was performed in 8 patients,combined with hypertension in 6 cases,diabetes mellitus in 4 cases,remote myocardial infarction in 5 cases,renal insufficiency in 2 cases,and cardiac insufficiency in 3 cases.Preoperative coronary angiography prompted the stenosis of left anterior descending artery(LAD) was 75%~100%,accompanied by 70%~98% stenosis of RCA or left circumflex artery.Cardiac ultrasonography tip of left ventricular ejection fraction was 0.41 to 0.62(0.55±0.16).Results There was no death,hemorrhage,stroke,arrhythmias,myocardial infarction,postoperative wound infection and other complications in this group.Beating heart coronary artery bypass grafting surgery time was 1.6 to 2.7(1.7±0.9)h.The Endotracheal intubation time was 5~13(7.8±2.9)h.The 24 h pleural effusion was 65~410(213.4±89.3)mL.The ICU stay time was 1~2 d(1.4±0.5)d.The postoperative hospital stay was 5~9(5.7±1.9)d.Follow-up duration was 0.7~2.7 years,there was no long-term myocardial infarction and death,and no re-operation.Conclusion One-stop composite technology(Hybrid) in treatment of multivessel coronary artery disease is a safe,effective surgical approach,its long-term efficacy remains to be verified by more clinical applications and clinical trials.
What problem does this paper attempt to address?